SUMOylation

By Targets:	Calcium Channel (1) E1/E2/E3 Enzyme (5) RAR/RXR (1) Sodium Channel (1) TAM Receptor (1) VD/VDR (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (2) Neurological Disease (1)
Click Chemistry:	Azide (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-110273

N106	Calcium Channel E1/E2/E3 Enzyme	Cardiovascular Disease
N106 is a first-in-class sarcoplasmic reticulum calcium ATPase (SERCA2a) SUMOylation activator. N106 directly activates the SUMO-activating enzyme, E1 ligase. N106 can be used for heart failure research .

HY-N0077

Ginkgolic Acid Maximum Cited Publications 10 Publications Verification Ginkgolic acid (15:1); Ginkgolic acid I; Romanicardic acid	E1/E2/E3 Enzyme	Cancer
Ginkgolic Acid is a natural compound that inhibits *SUMOylation* with an IC₅₀ of 3.0 μM in in vitro assay.

HY-111789

Subasumstat 5+ Cited Publications TAK-981	E1/E2/E3 Enzyme	Inflammation/Immunology Cancer
Subasumstat (TAK-981) is a first in class and selective inhibitor of the *SUMOylation* enzymatic cascade, with potential immune-activating and antineoplastic activities .

HY-114166

2-D08 4 Publications Verification	E1/E2/E3 Enzyme TAM Receptor	Cancer
2-D08 is a cell permeable, mechanistically unique inhibitor of protein *SUMOylation. 2-D08 also inhibits Axl* with an IC₅₀ of 0.49 nM.

HY-107218

11-Hydroxysugiol

RAR/RXR VD/VDR Infection

11-Hydroxysugiol regulates the SUMOylation of intracellular receptors by modulating RARα and vitamin D₃ receptor (VDR) .

11-Hydroxysugiol	RAR/RXR VD/VDR	Infection
11-Hydroxysugiol regulates the SUMOylation of intracellular receptors by modulating RARα and vitamin D₃ receptor (VDR) .

HY-114304

COH000 1 Publications Verification	E1/E2/E3 Enzyme	Cancer
COH000 is an allosteric, covalent and irreversible inhibitor of *ubiquitin-like 1-activating enzyme (SUMO-activating enzyme) (E1), with an IC₅₀* of 0.2 μM for SUMOylation in vitro .

HY-111789A

(S)-Subasumstat (S)-TAK-981	Others	Inflammation/Immunology Cancer
(S)-Subasumstat is the isomer of Subasumstat (HY-111789), and can be used as an experimental control. Subasumstat (TAK-981) is a first in class and selective inhibitor of the *SUMOylation* enzymatic cascade, with potential immune-activating and antineoplastic activities .

HY-145169

AZ194	Sodium Channel	Neurological Disease
AZ194 is a first-in-class, orally active inhibitor of CRMP2-Ubc9 interaction and inhibitor of NaV1.7 (IC₅₀=1.2 μM). AZ194 blocks SUMOylation of CRMP2 to selectively reduce the amount of surface-expressed NaV1.7. Antinociceptive effects .

HY-Y0493

HODHBt HOOBt
HODHBt (HOOBt) inhibits *STAT5-SUMO* interaction by blocking SUMOylation of phosphorylated STAT5. HODHBt enhances the magnitude of IL-15 signaling and significantly increases the natural killer (NK) cell cytotoxicity phenotype and function and the generation of cytokine-induced memory-like (CIML) natural killer (NK) cells. HODHBt can be used for research of HIV-infection and cancer .

Cat. No.	Product Name

HY-L024

Histone Modification Research Compound Library	614 compounds
A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases. MCE owns a unique collection of 614 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Histone Modification Research Compound Library

614 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 614 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0077

Ginkgolic Acid 5+ Cited Publications Ginkgolic acid (15:1); Ginkgolic acid I; Romanicardic acid	Monophenols Classification of Application Fields Ginkgoaceae Ketones, Aldehydes, Acids Source classification Phenols Plants Disease Research Fields Ginkgo biloba Cancer	E1/E2/E3 Enzyme
Ginkgolic Acid is a natural compound that inhibits *SUMOylation* with an IC₅₀ of 3.0 μM in in vitro assay.

Cat. No.	Product Name		Classification

HY-148835

AzGGK		Azide
AzGGK is an unnatural amino acid. AzGGK is site-specifically incorporated into proteins via genetic-code expansion. AzGGK can be used as site-specific probe for ubiquitylation and SUMOylation . AzGGK is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Natural
Products

Click Chemistry